Q4 2019 EPS Estimates for Harrow Health (HROW) Lifted by B. Riley

Harrow Health (NASDAQ:HROW) – Stock analysts at B. Riley lifted their Q4 2019 earnings per share (EPS) estimates for shares of Harrow Health in a research report issued to clients and investors on Wednesday, March 13th. B. Riley analyst A. D’silva now expects that the company will post earnings of $0.00 per share for the quarter, up from their previous forecast of ($0.01).

Separately, Zacks Investment Research upgraded Harrow Health from a “sell” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Friday.

HROW stock opened at $5.21 on Thursday. The company has a quick ratio of 0.88, a current ratio of 1.13 and a debt-to-equity ratio of 2.84. Harrow Health has a 1 year low of $1.71 and a 1 year high of $7.20. The stock has a market capitalization of $122.44 million, a PE ratio of -8.68 and a beta of 0.07.

Harrow Health (NASDAQ:HROW) last posted its earnings results on Tuesday, March 12th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.84 by ($0.07). Harrow Health had a negative net margin of 16.81% and a negative return on equity of 231.16%. The company had revenue of $11.38 million during the quarter, compared to analyst estimates of $10.92 million.

In other news, Director Robert J. Kammer sold 10,000 shares of the stock in a transaction dated Friday, March 1st. The stock was sold at an average price of $6.91, for a total value of $69,100.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 13.78% of the stock is currently owned by company insiders.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: Return On Assets

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.